君实生物(01877)2025年归母净亏损约8.74亿元 同比收窄31.74%

Core Viewpoint - Junshi Biosciences (01877) reported a total revenue of approximately 2.498 billion yuan for 2025, representing a year-on-year growth of 28.23% [1] - The net loss attributable to the parent company's owners was approximately 874 million yuan, a reduction of 31.74% compared to the previous year [1] - The basic loss per share was 0.87 yuan [1] Revenue Growth - The increase in revenue was primarily driven by significant sales growth of the core product, Toripalimab injection (brand name: Tuoyi®), in the domestic market [1] Loss Reduction - The reduction in losses was attributed to the implementation of a stock option incentive plan in 2025, which increased share-based payment expenses [1] - The company actively executed the "quality improvement and efficiency enhancement" action plan, continuously strengthening cost control measures [1] - Focused and efficient investment in the R&D pipeline, along with reduced unit production costs and improved sales efficiency, contributed to the decrease in loss amounts compared to the same period last year [1]